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Abstract
Background: Momordica charantia L. is a medicinal plant commonly used in the management of diabetes mellitus.
Objectives: We investigated the blood glucose lowering effect of  the methanolic fruit extract of  the Ugandan variety of  M.
charantia L. in alloxan-induced diabetic albino rats.
Methods: 500g of M. charantia powder were macerated in methanol and the extract administered to two groups of alloxan-
induced diabetic rats. The first group received 125mg/kg, the second 375mg/kg and a third group 7mg/ kg of metformin.
A fourth group received 1ml normal saline. Fasting blood glucose (FBG) levels were measured at 0.5,1,2,3,5,8 and 12 hours
and compared using one-way ANOVA.
Results: There was an initial rise in FBG for 1 hour after administration of extracts followed by steep reductions. Significant
reduction in FBG occurred at 2 hours for 125mg/kg of extract (-3.2%, 313±25.9 to 303±25.0mg/dL, p = 0.049), 375mg/
kg of extract (-3.9%, 356±19.7 to 342±20.3mg/dL, p = 0.001), and metformin (-2.6%, 344±21.7 to 335±21.1mg/dL, p =
0.003) when compared to normal saline. The maximum percentage reduction in FBG by both extracts occurred between 3
and 12 hours post dose.
Conclusions: The methanolic fruit extract of  M. charantia exhibits dose dependent hypoglycaemic activity in vivo.
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Diabetes Mellitus (DM) is a leading cause of illness
and death in developed countries and is epidemic in
many developing and newly industrialized countries.
Its macrovascular and microvascular complications
are debilitating. The prevalence of  diabetes in the
world at all ages was estimated to be 2.8% in 2000,
and it is expected to approximate 4.4% in the year
2030.The estimated global number of people of all
ages and sex with diabetes in 2000 was 171 million.
This is projected to increase to 366 million by 2030,
with about 4 million deaths every year attributed to
its complications1,2.
The estimated number of people with
diabetes in sub-Saharan Africa was 10.8 million in
2006, and this could rise to 18.7 million by 2025.
Major risk factors are similar to those of other
regions of  the world such as urbanization, obesity,
physical inactivity, or others that are not quite mutable
such as increasing age and ethnicity. Most African
countries still face a number of problems related to
the management and treatment of the disease, such
as critical shortage of diabetes medicine, the rising
cost of drugs and treatment, competition for
resources by HIV/AIDs, tuberculosis, and malaria.
The general lack of equipment to diagnose the disease
has hampered efforts to manage and control diabetes
mellitus3,2 . In Uganda, there is a new surge of non-
communicable diseases, among them diabetes and
this is partly due to changing lifestyle. Many urbanites
neither exercise nor do physical work. The number
of people with diabetes is now thought to have
passed a million, with 560,000 registered patients and
it is thought an equal number unknowingly have
undiagnosed disease4,5.
Anti-diabetic treatments or interventions are
grouped into three major categories; diet and exercise
which form part of  first line treatment of  diabetes,
insulin and oral hypoglycaemic agents. However, the
latter are often expensive and inaccessible to many
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low-income generating individuals in Uganda, given
their high cost and the sometimes long distance that
has to be travelled to the hospitals and health facilities
that avail them. Also, these drugs are not without
side effects and yet the treatment is life-long, due to
the chronic nature of disease. Because of this, some
patients use affordable and cost effective alternative
therapy for management of  diabetes in the form
of traditional medicines, which are both locally
available and cheap2, 4.
Several herbal remedies used in the management of
diabetes have been reported to possess hypoglycemic
effects6-11. Among these is Momordica charantia L Fam.
Cucurbitaceae (African cucumber, bitter gourd, bitter
melon) a medicinal plant used traditionally as an
antidiabetic, an emetic, a laxative, a tonic, and to treat
anaemia, arthritis, colds, fever, gout, infertility, kidney
stones, peptic ulcers, stomach ache and intestinal
helminthes12 . It is also used as an antimalarial, together
with related species, and as an abortifacient13-15. Some
pharmacological and safety studies of  this herb have
been carried out16,17. In addition to hypoglycaemic
activity, M.charantia has been shown to have
antioxidant18-20, anti-tumour21-25, neuroprotective26,
anti-inflammatory27-29 and antimicrobial activity30,31.
It has a resistance modifying effect for
aminoglycosides against methicillin-resistant
Staphylococcus aureus32. The plant is a source of urease
for urea determination33. Wan et al34 have also found
that M. charantia peroxidase can be used for
biotransformation of  piceatannol into
antihyperglycaemic oligomeric stilbenes.
This study aimed at investigating the effects
of the Ugandan variety of M. charantia L. methanolic
fruit extract on blood glucose levels in alloxan-
induced diabetic rats.
Methods
Plant collection and extraction
M. charantia ripe fruits were obtained from
Kabanyolo farm at the beginning of  the dry season
(December 2011 to February 2012).The herbarium
specimen was prepared and verified at the
Department of  Botany, Makerere University. Studies
have shown that hybridization occurs between
cultivated and wild varieties and that there is transfer
of genetic material between species35,36. The fresh
fruits were washed with tap water to remove dust
and other foreign material. They were then air dried
in the laboratory. The dry fruits were blended into a
powder form using a mortar and pestle. The
powder was weighed using a digital weighing
machine and weighed 138.6g.The powder was put
in a clean empty bottle and methanol added until it
covered the powder, with vigorous shaking to mix
the content. Methanol was added to make  2 litres.
The bottle was then corked and kept for 3 days
with occasional shaking to facilitate extraction of the
active component from the powder. A 2 litre
measuring cylinder and funnel and round bottomed
flask were cleaned and dried. The cotton was placed
in the neck of the funnel and placed on top of the
cylinder. The macerating mixture was poured into
the funnel to filter off the large size marc. The process
was repeated on the filtrate using Whartman filter
paper and the filtrate collected in a round bottomed
flask. The dry extract was obtained using a rotary
evaporator. The percentage yield was 17 percent.
The extract was stored in a vial in a cupboard.
Methanol was used because it is a polar
solvent and so hopefully would extract active
principles, which otherwise would have been
extracted using water. Also, it is easier to evaporate
compared to water.
Preparation of  the extract and metformin
5g of  extract were suspended in 25ml of  normal
saline solution to form a 200mg/ml suspension. One
tablet of  metformin (500mg) obtained from a
pharmacy was powdered and the powder dissolved
in 50ml of  normal saline to form a 10mg/ml
suspension.
Animal preparation
Twenty four male albino rats weighing between 150
and 180g were chosen in order to provide uniform
results and minimize error that occurs due to
variation in species, sex and weight. The animals were
obtained from the School of  Veterinary Medicine
and Animal Resources, Makerere University and
habituated at the Department of  Pharmacology,
College of Health Sciences, in cages for 3 days under
normal laboratory conditions of; temperature,
humidity and light (12 hours day, 12 hours night).They
were fed on standard animal feed and water ad
libitum.
Induction of Diabetes Mellitus in animals
The animals were made to fast for 18 hours receiving
only water. They were weighed and the Fasting Blood
Glucose (FBG) of each animal measured by bleeding
the diethyl ether anesthetized animal on the tail and
recording the glucose level using a glucometer. 1.5g
of alloxan powder, purchased from BDH
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laboratories, was dissolved in 25ml of  0.9% normal
saline to form a 60mg/ml solution. This was put in
a vial, autoclaved at 1210C for 3 hours and cooled.
Specific volumes of the solution were taken off and
injected into the tail veins of diethyl ethyl anesthetized
animals such that each animal got 65mg/kg body
weight37. The animals were then monitored for 5
days and elevation of  FBG confirmed after 18 hours.
Only animals with FBG above 200mg/dL were
used in the study.
Administration of test substances
Twenty four animals were randomly assigned to 4
groups of  6 each namely I, II, III and IV, and fasted
for 18 hours. Using a syringe and endogastric tube,
suspensions of the extract were administered by
gavage to restrained animals such that group IV
received 1ml normal saline, group III 7mg/kg body
weight of  metformin suspension, and groups I and
II 125mg/kg and 375mg/kg body weight of M.
charantia respectively.
Measurement of  Fasting Blood Glucose
Blood drops were obtained by piercing the tip of
diethyl ether anesthetized tails of the rats and FBG
measured using a glucometer. The fasting blood
glucose levels were measured at 0, 0.5,1,2,3,5,8 and
12 hours after administration of  the substances.
Statistical analysis
The means of fasting blood glucose levels for the
test and control groups were compared at different
times by one-way analysis of  variance (ANOVA)
using SPSS 11 software. A p value <0.05 was
considered statistically significant.
Ethical considerations
This study was approved by the Institutional Review
Committee of the School of Medicine, College of
Health Sciences, Makerere University. All experiments
were conducted in accordance with internationally
accepted principles for animal use and care.
Results
There was an initial increase in the FBG when the
extract was administered, which lasted the first 1 hour.
The rise was greater with 125mg/kg (13.0%) than
375mg/kg (8.9%) of the extract. Thereafter, there
was a significant reduction in FBG at 2 hours for
125mg/kg of extract (-3.2%, 313±25.9 to
303±25.0mg/dL, p = 0.049), 375mg/kg of extract
(-3.9%, 356±19.7 to 342±20.3mg/dL, p = 0.001),
and metformin (-2.6%, 344±21.7 to 335±21.1mg/
dL, p = 0.003) when compared to normal saline
(figure 1). The maximum percentage reduction in
FBG by both extracts occurred between 3 and 12
hours post dose (table 1).
Figure 1: Mean blood glucose (mg/dL) after administration of methanolic fruit extract of Momordica
charantia and metformin in alloxan-induced diabetic rats (n=6)
SE = standard error of mean
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Table 1: Percentage glycaemic change after administration of  methanolic fruit extract of  Momordica
charantia L. in alloxan-induced diabetic rats (n=6)
Treatment Percent glycaemic change*
           Time (Hours)
0 0.5 1 2 3 5 8 12
Normal saline 1ml 0 -2.7 -2.8  0.4 -4.1  4.3 -4.5 -4.3
Metformin 7mg/kg 0 -3.5 -2.8 -2.6 -2.4 -3.4 -2.8  -3.3
M. charantia extract 125mg/kg 0  4.3  8.3 -3.2 -5.3 -6.9 -6.2 -10.0
M. charantia extract 375mg/kg 0  4.6  4.1 -3.9 -6.7 -4.4 -5.9 -13.6
*Negative values indicate reductions
The subsequent FBG reductions 2 hours after
administration of extract remained significant up to
12 hours for 375mg/kg, while that of 125mg/kg
of  extract was significant after the third hour. The
percentage reductions for both concentrations of
the extract were greater than those of  metformin
between 8 and 12 hours (14% and 10% as compared
to 3% respectively). The effect on FBG of 375mg/
kg of the methanolic extract was comparable to that
of  metformin (p > 0.05 between 2 and 12 hours).
Discussion
The antidiabetic effect of M. charantia was
investigated and the results show that at 2 hours,
both concentrations of the methanolic fruit extract
exhibited declines in blood glucose, with 375mg/
kg of extract having a greater effect than 125mg/
kg of extract. The onset of glucose lowering was
not as rapid as with metformin, yet the trajectory
appeared superior. Both the extract and metformin
lowered blood glucose levels without inducing
hypoglycaemia. The initial rise in blood glucose could
be attributed to the carbohydrate content of the plant
or as a result of a physiological phenomenon38. This
was not observed in mice administered normal
saline. This initial rise in FBG seems to offset the
early anti-hyperglycaemic effect of the crude extract.
Kolawole et al39 showed that the methanolic
fruit extract of M. charantia decreased blood glucose
in both normal and diabetic animals, comparable to
10mg/kg of chlorpropramide in doses of 400 to
600mg/kg. Mamun40 also found a significant
decrease in blood glucose and increase in serum
insulin when powdered fruits of the plant were
administered to diabetic rats, while Rathnaker et al 41
have demonstrated the hypoglycaemic effect of a
polyherbal product containing M. charantia. In
another study, a different species, Momordica cymbalaria
was found to produce a time-dependent decrease
in fasting blood glucose levels42. However, a
systematic review of four Randomized Controlled
Trials of  M. charantia for type 2 DM by Ooi et al43
showed no difference with placebo, metformin or
glibenclamide indicating the need for further clinical
studies, standardization and quality control of
preparations.
In this study, the anti-hyperglycaemic effects
of  metformin (7mg/kg) and 375mg/kg extract
were more or less similar. While metformin lowers
FBG concentrations by decreasing hepatic
gluconeogenesis and increasing insulin-stimulated
glucose uptake by skeletal muscle and adipose tissues,
M. charantia appears to act by repairing damaged
Beta-cells, increasing insulin secretion, enhancing
insulin sensitivity in peripheral tissue by promoting
glucose uptake, inhibition of hepatic
gluconeogenesis,  decreasing glucose absorption by
inhibiting glucosidase and disaccharidases in the
intestine, and enhancing the activity of AMP-activated
protein kinase44 . Indeed some of the constituents
of the extract like oleanolic acid 3-O-glucuronide
and momordin exert their anti-hyperglycemic effect
by inhibiting glucose transport at the brush border
of the small intestine. The aqueous extract of the
unripe fruit of M. charantia has been shown to
partially stimulate insulin release from isolated Beta-
cells of the pancreas in rats, while the fruit juice
significantly increased the number of Beta-cells6. M.
charantia has also been reported to inhibit 11Beta-
hydroxysteroid dehydrogenase, a potential anti-
diabetes target45.
Major active principles in M. charantia are
sterols, triterpenes, glycosides notably momordin Ic,
charantin, goyaglycosides, momordicosides and
other cucurbitane glycosides, goyasaponins, the
alkaloid momordicin, phenolic compounds, tannins,
flavonoids, carotenoids and bioactive proteins like
polypeptide p and alpha-momorcharin12,44,46-50. The
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oleanane-glycoside momordin Ic and cucurbitane-
type triterpenoid glycosides especially charantin and
polypeptide p have been shown to have
hypoglycaemic activity44,51-54. While Harazika et al55
have demonstrated that momordicilin a triterpene,
is a potent inhibitor of glycogen synthase kinase-3,
an enzyme involved in glucose homeostasis and
potential target for anti-diabetic compounds.
These findings provide further evidence for
hypoglycemic activity of M. charantia similar to that
seen in other members of  the Cucurbitaceae Family.
Limitations
It is noteworthy that initial blood glucose levels were
slightly different for extract, metformin and saline
groups at baseline. This was difficult to control.
However, we determined the rate and extent of
decrease in blood glucose, which was greater for
the metformin and extract groups compared to
normal saline.
Conclusion
The study revealed that the methanolic fruit extract
of M. charantia exhibited anti-hyperglycaemic effects
comparable to those of  metformin, in appropriate
doses, in alloxan-induced diabetic rats, but the initial
effect appears to be offset by the carbohydrate
content of the extract. The anti-hyperglycaemic
activity increased with an increase in dose of extract.
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